Targeting the DNA Damage Response Pathway: The Evolving Role of PARP Inhibitors in Cancer Therapy

Activity Details
  • Credit Amounts:
  • Cost: Free
  • Release: Jul 31, 2017
  • Expires: Jul 31, 2018
  • Average User Rating:
    ( Ratings)

Click Here to Complete Activity

 

Needs Statement

DNA damage response (DDR) is an essential mechanism by which cells ensure the stability of the genome through various repair pathways. Nearly all cancers have deficiencies in one or two DDR pathways, resulting in an increased dependence on alternate, less accurate repair pathways.1,2 While these DDR deficiencies favor tumor progression, they also make cells particularly vulnerable to therapies that inhibit compensatory pathways, which result in “synthetic lethality” or the death of the DDR defective cell. Poly ADP-ribose polymerase (PARP) inhibitors were developed to exploit such vulnerabilities in tumor cells, and have thus far shown to be effective in BRCA mutation-positive tumors including ovarian, breast, and a variety of other cancers.3

Participants of this activity will gain an appreciation of the latest clinical developments in targeting DDR for the treatment of ovarian, breast, and other cancers, including updates on the current and emerging prospects of PARP inhibitors, as well as strategies for the oncology nurse to optimize therapy, anticipate adverse events, and improve adherence. The importance of recommended genetic testing and counseling in patients with possible pathogenic DDR mutations, their implications on patient management strategies and the role of the oncology nurse in genetic counseling will also be discussed.

1van Gent DC, et al. Mol Biol Cell. 2016. 2O’Connor MJ, et al. Mol Cell. 2015. 3Cerrato A, et al. J Exp Clin Canc Res. 2016.

Target Audience

This activity is designed to meet the educational needs of oncology nurses and nurse practitioners.

Objectives

Upon completion of this activity, participants will be able to:

1. Outline key mechanisms in the DNA damage response pathway and their role in tumor suppression.

2. Appraise the importance of recommended genetic testing and counseling in patients with possible pathogenic DNA damage response mutations and their implications on patient management strategies.

3. Assess the current and emerging data on safety and efficacy of DNA damage response targeting therapies, such as PARP inhibitors, in patients with ovarian, breast, prostate, or pancreatic cancer.

4. Using a case-based approach, evaluate challenging questions regarding the use of PARP inhibitors and discuss ways the oncology nurse can optimize therapy, anticipate adverse effects, and play a role in improving adherence strategies.

Faculty Disclosure

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner:

Vanessa Carranza, PharmD: Dr. Carranza has no relevant financial relationships to disclose in relation to the content of this activity.

Presenters:

Paula J. Anastasia, RN, MN, AOCN (Activity Chair): Paula Anastasia has disclosed that she is a member of the speakers' bureaus for Clovis and Genentech.

Lisa Arvine, RN, MSN, ANP-BC, WHNP-BC: Lisa Arvine has no relevant financial relationships to disclose in relation to the content of this activity.

Bobbie J. Rimel, MD: Dr. Rimel has disclosed that she is a consultant for Genentech and Tesaro.

Nadine M. Tung, MD: Dr. Tung has disclosed that she receives grant/research support from Ambry Genetics and AstraZeneca.

Peer Reviewer:

Chrisann A. Winslow, RN, BSN, MSN(R), AOCN: Chrisann Winslow has disclosed that she is a member of the speakers' bureau for Clovis.